What is the 13F Pro Quality Score for AXSM?

13F Pro ranks Axsome Therapeutics, Inc. (AXSM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AXSM's current score at https://13fpro.ai/company/AXSM (free sign-up required for the full ranking).

Where does 13F Pro source AXSM data?

All Axsome Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Axsome Therapeutics, Inc. files with the SEC under CIK 1579428. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AXSM in?

Axsome Therapeutics, Inc. (AXSM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AXSM research updated on 13F Pro?

AXSM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Axsome Therapeutics, Inc.(AXSM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1579428 AXSM stock profile & AI dashboard →

13F Pro Quality Score

40.8/100

Rank #2,087 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

95.4/100

Profitability

16.0/100

Balance Sheet

8.6/100

Earnings Quality

37.9/100

Free Cash Flow

17.1/100

Institutional Flow

39.5/100

Revenue Scale

45.2/100

Dilution Risk

12.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AXSM Scores 41/100

exact factor attribution · 2026-09-11

AXSM's composite is driven by revenue growth, held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.1 pts

95th pct

Earnings growth

+0.3 pts

55th pct

Institutional flow

-0.5 pts

40th pct

Scale

-0.7 pts

45th pct

Earnings quality

-1.2 pts

38th pct

Shareholder dilution

-1.9 pts

12th pct

Capital efficiency

-4.1 pts

9th pct

Free cash flow

-4.9 pts

17th pct

Profitability

-5.1 pts

16th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AXSM Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Axsome Therapeutics, Inc. (AXSM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AXSM at 40.8/100 on a 32-signal composite quality model, placing it at rank #2,087 of 2,961 stocks — the bottom half of the AI-ranked universe. AXSM scores in the top quartile across revenue growth (95.4). Areas of concern include balance sheet strength (8.6) and profitability (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Axsome Therapeutics, Inc. reports quarterly revenue of $218.4M, net income of $-51.3M, an operating margin of -22.7%. Top institutional holders of AXSM by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. AXSM trades on the Nasdaq exchange and files with the SEC under CIK 1579428. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AXSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Axsome Therapeutics, Inc. directly from SEC EDGAR. Axsome Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 18 and 42 since 2023, currently 40.8 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.

✦

Fun facts about Axsome Therapeutics, Inc.

Quirks, history, and lore behind AXSM — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in New York City.
2
The Numbers
Revenue in the low hundreds of millions of dollars annually — a company still in its commercial adolescence, having only recently moved from pure R&D to actual product sales.
3
The History
Founded in the 2010s, it spent years quietly developing drugs targeting central nervous system disorders before finally winning hard-fought FDA approvals.
4
The Secret
Its pipeline focuses almost entirely on CNS conditions — think depression, narcolepsy, and Alzheimer's agitation — areas where Big Pharma largely gave up for decades.
5
The Lore
Its lead approved product, Auvelity, is a fast-acting oral antidepressant that works through a novel NMDA receptor mechanism — a totally different pathway than traditional SSRIs.
6
The Giveaway
With Auvelity for major depressive disorder and Sunosi in its portfolio, this company's ticker is practically a battle cry: AXSM.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$218.4M

Net Income

Q2 2026

$-51.3M

Free Cash Flow

Q2 2026

$-33.4M

Operating Margin

Q2 2026

-22.7%

ROIC

Q2 2026

-73.2%

D/E Ratio

Q2 2026

2.26

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+65.5% YoY

$638.5MFY 2025

FY22 $0.00FY23 $270.6MFY24 $385.7MFY25 $638.5M

Net Income

+36.2% YoY

$-183.2MFY 2025

FY22 $-187.1MFY23 $-239.2MFY24 $-287.2MFY25 $-183.2M

Operating Income

+40.6% YoY

$-166.8MFY 2025

FY22 $-179.8MFY23 $-231.8MFY24 $-280.6MFY25 $-166.8M

EPS (Diluted)

+38.6% YoY

$-3.68FY 2025

FY22 $-4.60FY23 $-5.27FY24 $-5.99FY25 $-3.68

Total Assets

+21.3% YoY

$689.8MFY 2025

FY22 $331.5MFY23 $588.2MFY24 $568.5MFY25 $689.8M

Total Debt

+3.9% YoY

$187.7MFY 2025

FY22 $94.3MFY23 $178.1MFY24 $180.7MFY25 $187.7M

Op. Cash Flow

+27.3% YoY

$-93.4MFY 2025

FY22 $-116.5MFY23 $-145.1MFY24 $-128.4MFY25 $-93.4M

Free Cash Flow

+27.0% YoY

$-93.9MFY 2025

FY22 $-117.2MFY23 $-145.7MFY24 $-128.7MFY25 $-93.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$638.5M +65.5%	$385.7M +42.5%	$270.6M	$0.00	—	—
Net Income	$-183.2M +36.2%	$-287.2M -20.1%	$-239.2M -27.8%	$-187.1M -43.5%	$-130.4M -26.7%	$-102.9M
Operating Income	$-166.8M +40.6%	$-280.6M -21.0%	$-231.8M -28.9%	$-179.8M -44.2%	$-124.7M -25.8%	$-99.1M
EPS (Diluted)	$-3.68 +38.6%	$-5.99 -13.7%	$-5.27 -14.6%	$-4.60 -32.6%	$-3.47 -25.3%	$-2.77
Total Assets	$689.8M +21.3%	$568.5M -3.4%	$588.2M +77.5%	$331.5M +277.6%	$87.8M -52.8%	$186.1M
Total Debt	$187.7M +3.9%	$180.7M +1.5%	$178.1M +88.9%	$94.3M +92.0%	$49.1M +1.6%	$48.3M
Operating Cash Flow	$-93.4M +27.3%	$-128.4M +11.5%	$-145.1M -24.5%	$-116.5M -7.7%	$-108.2M -37.9%	$-78.5M
Free Cash Flow	$-93.9M +27.0%	$-128.7M +11.7%	$-145.7M -24.3%	$-117.2M -8.0%	$-108.5M -38.3%	$-78.5M

Get alerted when AXSM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Axsome Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AXSM

BlackRock, Inc.
$759.7M3,103,708 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$485.5M1,983,514 sh
VANGUARD CAPITAL MANAGEMENT LLC
$481.0M1,965,086 sh
Invesco Ltd.
$409.2M1,671,684 sh
FMR LLC
$376.7M1,539,163 sh
GEODE CAPITAL MANAGEMENT, LLC
$236.8M967,172 sh
MORGAN STANLEY
$196.8M804,082 sh
STATE STREET CORP
$192.3M785,661 sh
Deep Track Capital, LP
$171.3M700,000 sh
TWO SIGMA INVESTMENTS, LP
$163.9M669,478 sh

Fund	Value	Shares
BlackRock, Inc.	$759.7M	3,103,708
VANGUARD PORTFOLIO MANAGEMENT LLC	$485.5M	1,983,514
VANGUARD CAPITAL MANAGEMENT LLC	$481.0M	1,965,086
Invesco Ltd.	$409.2M	1,671,684
FMR LLC	$376.7M	1,539,163
GEODE CAPITAL MANAGEMENT, LLC	$236.8M	967,172
MORGAN STANLEY	$196.8M	804,082
STATE STREET CORP	$192.3M	785,661
Deep Track Capital, LP	$171.3M	700,000
TWO SIGMA INVESTMENTS, LP	$163.9M	669,478

Companies Similar to AXSM

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

INSM

INSMED Inc

AI score

Very similar · 24 shared holders

Hood River Capital Management LLC Integral Health Asset Management, LLC FRONTIER CAPITAL MANAGEMENT CO LLC

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

AI score

Very similar · 25 shared holders

Hood River Capital Management LLC DRIEHAUS CAPITAL MANAGEMENT LLC EVENTIDE ASSET MANAGEMENT, LLC

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 27 shared holders

Hood River Capital Management LLC Clearbridge Investments, LLC DRIEHAUS CAPITAL MANAGEMENT LLC

RARE

Ultragenyx Pharmaceutical Inc.

AI score

Similar quality profile · 18 shared holders

FRONTIER CAPITAL MANAGEMENT CO LLC Sofinnova Ventures Inc Eagle Health Investments LP

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Shared smart-money ownership · 37 shared holders

EVENTIDE ASSET MANAGEMENT, LLC Clearbridge Investments, LLC LOOMIS SAYLES & CO L P

BBIO

BridgeBio Pharma, Inc.

AI score

Shared smart-money ownership · 34 shared holders

Hood River Capital Management LLC FRONTIER CAPITAL MANAGEMENT CO LLC Clearbridge Investments, LLC

Guardant Health, Inc.

AI score

Similar quality profile · 35 shared holders

Deep Track Capital, LP Hood River Capital Management LLC DRIEHAUS CAPITAL MANAGEMENT LLC

NTRA

Natera, Inc.

AI score

Similar quality profile · 16 shared holders

DRIEHAUS CAPITAL MANAGEMENT LLC Clearbridge Investments, LLC FRONTIER CAPITAL MANAGEMENT CO LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AXSM on your watchlist

Track score changes the day Axsome Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AXSM a good stock to buy?

13F Pro's AI-powered analysis of Axsome Therapeutics, Inc. (AXSM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AXSM are available on the AXSM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AXSM is classified as a large company.

Which hedge funds own AXSM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AXSM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Axsome Therapeutics, Inc.'s investment landscape.